Deferiprone
Mechanism :
Deferiprone is an oral drug that chelates iron and is used to treat thalassaemia major.
Indication :
- Iron overload
- Hemolytic anemia on multiple transfusion
- Thalassemia major
Contraindications :
Contraindicated if there is a history of agranulocytosis or recurrent episodes of neutropenia.
Dosing :
Oral
>6 years:
25 mg/kg/dose or 250 mg dose 3 times daily. Max: 100 mg/kg/day.
Adverse Effect :
Nausea, vomiting, altered taste, abdominal pain, increased appetite, reddish/brown urine, joint pain, agranulocytosis, neutropenia, arthropathy.
Interaction :
Neutropenic Drugs: Patients should not take any other neutropenic drugs.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Give 50% of dose and monitor |
| <10 | Give 50% of dose and monitor |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unknown dialysability. Dose as in GFR<10 mL/min |
| HD | Dialysed. Dose as in GFR<10 mL/min |
| HDF/High flux | Dialysed. Dose as in GFR<10 mL/min |
| CAV/VVHD | Dialysed. Dose as in GFR=10–20 mL/min |
Hepatic Dose :
No dosage adjustments are recommended. Data for use in severe hepatic impairment is lacking.